Tesana

Tesana is a clinical-stage biotechnology company focused on developing next-generation oral therapies for metabolic diseases, with a primary emphasis on obesity and type 2 diabetes. The company is advancing a pipeline of small molecule agonists targeting the GLP-1 and GIP receptors, aiming to provide more accessible and convenient alternatives to current injectable treatments. By leveraging deep expertise in metabolic signaling, Tesana seeks to optimize weight loss efficacy and metabolic health while improving patient adherence through oral delivery. The company's lead programs are designed to address the global epidemic of metabolic dysfunction with potent, well-tolerated oral candidates.